Table 3. Randomized Controlled Screening Trials: Fecal Occult Blood Testing
| Site | Population Size | Positivity Rate (%) | % Cancers Localizeda | Testing Interval | Relative Mortality Reduction | |
| Screened | Control | |||||
| Minnesota [5,6] | 48,000 | Unrehydrated: 2.4% | 59 | 53 | Annual | 33% |
| Rehydrated: 9.8% | Biennial | 21% | ||||
| United Kingdom [10] | 150,000 | Unrehydrated: 2.1% | 52 | 44 | Biennial | 15% |
| Denmark [14] | 62,000 | Unrehydrated: 1.0% | 56 | 48 | Biennial | 18% |
| Sweden [28] | 68,308 | Unrehydrated: 1.9% | 52 | 50 | 16% | |
| Rehydrated: 5.8% | ||||||
| N/A = not available. | ||||||
| a% Localized = T1–3 N0 M0. |
References
- Mandel JS, Bond JH, Church TR, et al.: Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 328 (19): 1365-71, 1993. [PUBMED Abstract]
- Mandel JS, Church TR, Ederer F, et al.: Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst 91 (5): 434-7, 1999. [PUBMED Abstract]
- Hardcastle JD, Chamberlain JO, Robinson MH, et al.: Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 348 (9040): 1472-7, 1996. [PUBMED Abstract]
- Kronborg O, Fenger C, Olsen J, et al.: Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 348 (9040): 1467-71, 1996. [PUBMED Abstract]
- Kewenter J, Björk S, Haglind E, et al.: Screening and rescreening for colorectal cancer. A controlled trial of fecal occult blood testing in 27,700 subjects. Cancer 62 (3): 645-51, 1988. [PUBMED Abstract]
